Schröder Katharina, Finis David, Harmel Jens, Ringelstein Marius, Hartung Hans-Peter, Geerling Gerd, Aktas Orhan, Guthoff Rainer
Department of Ophthalmology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
Department of Neurology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
Mult Scler Relat Disord. 2015 Sep;4(5):406-408. doi: 10.1016/j.msard.2015.06.015. Epub 2015 Jul 2.
Fingolimod is a potent drug in relapsing forms of multiple sclerosis. Visual impairment due to fingolimod-associated macular edema (FAME) usually leads to discontinuation of fingolimod therapy.
We report on a 24-year old woman with bilateral FAME.
We continued fingolimod and added oral acetazolamide, which led to recovery of visual acuity and regression of macular edema. However, fingolimod had to be discontinued when fluorescein angiography revealed an enlarged foveal avascular zone.
Oral acetazolamide might be a treatment option for FAME, while ischemic conversion may be limiting. Ophthalmologic assessments are mandatory for follow-up when fingolimod therapy is continued after onset of FAME.
芬戈莫德是治疗复发型多发性硬化症的一种有效药物。由芬戈莫德相关黄斑水肿（FAME）导致的视力损害通常会使芬戈莫德治疗中断。
我们报告了一名患有双侧FAME的24岁女性。
我们继续使用芬戈莫德并加用口服乙酰唑胺，这导致视力恢复和黄斑水肿消退。然而，当荧光素血管造影显示中心凹无血管区扩大时，不得不停用芬戈莫德。
口服乙酰唑胺可能是FAME的一种治疗选择，而缺血性转变可能会限制其应用。FAME发作后继续芬戈莫德治疗时，眼科评估对于随访是必不可少的。
Zotero 插件